Free tool
Oncology stocks
We cover 45 companies grouped under the Oncology theme. The median market value in the group is $4.67B. Across the group, the median move over the past trading day is +1.63%. 82% of the 44 with a 200-day average trade above it. Price change over the past year runs from −22.3% to +333.2% across the middle 80 percent of the group, with a median of +53.5%. Across the group, 1 company currently carries a tier A volume signal.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
45 of 319 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return |
|---|---|---|---|---|---|
| BMY | Bristol-Myers Squibb Company | $67.92 | +8.57% | +28.36% | +49.31% |
| 4519.T | Chugai Pharmaceutical Co., Ltd. | 7,050.00 JPY | +0.73% | −17.21% | +12.47% |
| RVMD | Revolution Medicines, Inc. | $211.38 | +12.39% | +167.50% | +492.60% |
| ONC | BeOne Medicines AG | $376.37 | +15.49% | +21.01% | +21.95% |
| 4568.T | Daiichi Sankyo Company, Limited | 2,923.00 JPY | +1.16% | −16.08% | −15.95% |
| BNTX | BioNTech SE | $114.05 | +25.21% | +17.95% | +8.55% |
| INCY | Incyte Corporation | $129.72 | +9.13% | +27.90% | +53.04% |
| GMAB | Genmab A/S | $34.36 | +19.31% | +7.98% | +41.34% |
| GE9.DE | GENMAB AS N | 283.30 EUR | +10.97% | +5.71% | −14.41% |
| 0J9P.L | Incyte Corporation | $130.13 | +1.97% | +30.41% | +53.55% |
| IPN.PA | Ipsen S.A. | 162.60 EUR | +1.37% | +40.05% | +39.21% |
| EXEL | Exelixis, Inc. | $56.72 | +1.63% | +30.15% | +49.66% |
| 0IJO.L | Exelixis, Inc. | $56.16 | +3.33% | +30.00% | +44.33% |
| 0M2N.L | Orion Oyj | 80.50 EUR | +12.46% | +29.29% | +19.68% |
| SMMT | Summit Therapeutics Inc. | $13.36 | +1.95% | −23.74% | −49.14% |
| NUVL | Nuvalent Inc | $123.96 | 0.00% | +22.93% | +67.40% |
| 4528.T | Ono Pharmaceutical Co., Ltd. | 2,511.00 JPY | +3.89% | +16.57% | +62.22% |
| CGON | CG Oncology, Inc. | $78.95 | +7.39% | +88.92% | +210.58% |
| E2XE34.SA | Exelixis, Inc. | 137.40 BRL | −2.25% | +23.92% | +23.92% |
| LNTH | Lantheus Holdings, Inc. | $100.87 | −6.63% | +49.95% | +79.61% |
| COGT | Cogent Biosciences, Inc. | $36.80 | −9.00% | +5.93% | +212.13% |
| ERAS | Erasca, Inc. | $17.76 | −5.88% | +394.71% | +1016.98% |
| 000100.KS | Yuhan Corporation | 86,000.00 KRW | +21.64% | −23.35% | −25.59% |
| 0I3Q.L | Corcept Therapeutics Incorporated | $122.59 | −2.12% | +233.46% | +75.99% |
| RLAY | Relay Therapeutics, Inc. | $20.57 | +10.35% | +151.47% | +486.04% |
| ELVN | Enliven Therapeutics, Inc. | $61.01 | +15.69% | +292.60% | +205.89% |
| CELC | Celcuity Inc. | $92.27 | +12.16% | −8.23% | +87.35% |
| TNGX | Tango Therapeutics, Inc. | $24.51 | −8.27% | +174.47% | +264.73% |
| IDYA | IDEAYA Biosciences, Inc. | $42.48 | +15.53% | +25.49% | +71.91% |
| RCUS | Arcus Biosciences, Inc. | $31.57 | +13.40% | +35.55% | +211.03% |
| TLX | Telix Pharmaceuticals Limited | $11.68 | +17.03% | +53.28% | −4.26% |
| TLX.AX | Telix Pharmaceuticals Limited | 16.06 AUD | +10.99% | +41.37% | −12.72% |
| 000105.KS | Yuhan Corporation | 71,600.00 KRW | +17.76% | −29.29% | −31.05% |
| IMNM | Immunome, Inc. | $29.39 | +30.14% | +41.14% | +196.22% |
| ZLAB | Zai Lab Limited | $26.17 | +40.40% | +51.01% | −23.10% |
| SLS | SELLAS Life Sciences Group, Inc. | $14.09 | +29.98% | +223.91% | +637.70% |
| NRIX | Nurix Therapeutics, Inc. | $26.95 | +15.02% | +49.22% | +178.70% |
| NUVB | Nuvation Bio Inc. | $7.10 | +6.61% | −17.25% | +146.53% |
| URGN | UroGen Pharma Ltd. | $46.36 | +11.82% | +104.14% | +150.59% |
| XNCR | Xencor, Inc. Common Stock | $29.30 | +47.53% | +96.38% | +265.79% |
| HCM | HUTCHMED (China) Limited | $12.26 | +10.25% | −10.18% | −23.04% |
| HCM.L | HUTCHMED (China) Limited | 178.00 GBP | +0.85% | −12.75% | −21.24% |
| NANO.PA | Nanobiotix S.A. | 34.14 EUR | +3.96% | +79.68% | +341.09% |
| NBTX | Nanobiotix S.A. | $41.51 | +3.31% | +87.57% | +321.42% |
| NVCR | NovoCure Limited | $17.62 | +3.46% | +34.30% | +50.60% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.